Know more... - Pancreatic Cancer India

Dr Bhawna Sirohi’s CV
CURRICULUM VITAE
PERSONAL DETAILS:
Name:
Bhawna Sirohi
Telephone Mobile 0091 (0) 99300 33980
Email
Bhawna.sirohi@btinternet.com
GMC Registration number Full Medical 4758297 (Specialist register of Medical
Oncology)
Delhi Medical Council 45709
Mahrashtra Medical Council 2012/10/2916
Date of birth September 13, 1968
Permanent address A-162 Defence Colony, Mawana Road
Meerut, UP. India
EDUCATION:
1991 MBBS
I: Government Medical College, Nagpur University, Mahrashtra, India
II-III: Lala Lajpat Rai Medical College (LLRM), Meerut University, UP, India
Overall 1 st rank aggregate in all three MBBS examinations
Distinction in Anatomy, Biochemistry, Forensic Medicine, Obs & Gynae
Certificate of honours in Pathology, Pharmacology, Surgery
Gold Medal in Anatomy, Obs & Gynae.
1994 DCH –Diploma in Child Health
Lala Lajpat Rai Medical College (LLRM), Meerut University, UP, India
1997 Completed training in Medical Oncology at Tata Cancer Hospital, Mumbai
2007 European School of Medical Oncology accreditation
2009 Certificate of Eligibility for Specialist Registration in Medical Oncology, On
Specialist register of General Medical Council, UK
2009 Affiliate Member Royal College of Physicians, London
CURRENT APPOINTMENT:
1

Dr Bhawna Sirohi’s CV
May 2012 –continuing
Consultant Medical Oncologist –GI & Breast Unit
Tata Memorial Centre
Mumbai-400012
PREVIOUS APPOINTMENTS:
July 2010 – April 2012
Head of Medical & Haemato-Oncology
Artemis Cancer Centre
Artemis Healthsciences, Sector -51
Gurgaon and Delhi, India
Artemis is a 300-bedded tertiary care private hospital in the NCR region. Since I
joined, following have been initiated /implemented within the oncology department
1. Optimised daycare facility with oncology trained nurses and an admixture lab
with laminar flow.
2. Regular courses for the nurses in handling chemotherapy, infection control,
hand hygiene and care of central venous access devices.
3. Monthly cancer awareness programmes and clinical screening camps in the
nearby villages and resident welfare associations through the hospital and
NICCI (New India Cancer Charity Initiative)
4. Complimentary palliative care program in collaboration with Cansupport
5. Joint site-specific clinics for Breast, GI, Gynaecological and head & neck
cancers.
6. Home Care program for end of life care, palliative care, administration of
infusions, injections and blood sampling prior to chemotherapy.
7. DNB inspection for medical oncology
8. NABH re-accreditation for medical oncology
9. Patient support group meetings.
10. Antibiotic stewardship committee to rationalise the use of antibiotics within
the hospital
11. Prospectively maintained database which reports to the Haryana and IRCH
Cancer registry
12. Clinical trials unit.
October 2009 –June 2010 Max Cancer Centre, Max Healthcare, New Delhi
Max is tertiary care hospital with 8 hospitals all over National capital region. This
was my first appointment on return from UK as Director and Chief consultant in
Medical Oncology (Pan-Max). I had been involved in setting up of the medical
oncology unit from Jan 2009 onwards with weekly tele and video-conferences at two
sites (Saket and Patparganj). I set up an international standard (designed on the basis
of Royal Marsden MHRA standard facility with support room, changing and clean
room) laminar flow facility for chemotherapy admixing for the safety of the nurses
and patients ay both the sites. This was manned by oncology pharmacists. I was
instrumental in getting the unit thorough NABH accreditation and was working
towards planning for JCI accreditation. During my period at Max, I was a member of
the Hospital ethics committee, institutional review board, consumer advocacy board,
Hospital infection control committee, central pharmacy and therapeutics committee.
June 2009 –September 2009 Guy’s and St Thomas’ NHS foundation Trust
London
2

Dr Bhawna Sirohi’s CV
I joined Guys and St Thomas’ as locum consultant medical oncologist within the
breast, GI and Lung unit. I also did a breast cancer clinic once a week at Kings
college Hospital. This helped me develop crucial ties with both the institutions.
I was closely involved in the teaching of specialist registrars and senior house
officers.
May 2008 – June 2009 Addenbrookes hospital, Hills Road, Cambridge, CB2 2QQ
I joined as consultant medical oncologist within the GI and melanoma unit. I was
chief and principal investigator on trials in GI and skin cancers. I was involved in the
teaching of specialist registrars, senior house officers and medical students from
various colleges in Cambridge.
Feb 1998-May 2008 Royal Marsden NHS Foundation Trust, Chelsea and Sutton,
London
I joined as a research fellow in the Haemato-Oncology Unit with Prof Ray Powles in
February 1998 and within a year, I was fully responsible for the day to day running of
the unit, coordination of clinical trials (from Phase I to III), recruitment of research
nurses, fellows, data managers and doctors. During my tenure at the Royal Marsden, I
continued working at senior level of a specialist registrar /honorary consultant while
my accreditation based on experience with the UK Joint Royal College of physicians
training board was ongoing. I also worked at Parkside Oncology clinic, Wimbeldon as
honorary Consultant from Jan 2004 onwards.
Consultants I have worked closely with:
Prof Ray Powles, Prof Daniel Catovsky, Dr Jennifer Treleaven (Haemato-oncology),
Prof Alan Horwich, Prof David Dearnaley, Dr Robert Huddart, Dr Chris Parker
(Urology), Dr Mary O’Brien (Lung , Breast), Prof David Cunningham, Dr Geoffery
Chong (GI/Lymphoma), Prof Ian Smith, Dr Stephen Johnston, Dr Mark Allen
(Breast), Prof Martin Gore, Dr Michelle Harrison, Dr Ana Montes (Gynae/Renal and
Melanoma), Dr Frank Saran, Dr Diana Tait, Dr Gill Ross (Clinical Oncology), Dr
Julia Riley, Dr Andrew Davies (Palliative Care), Prof Peter Mortimer (Dermatology),
Dr Jervoise Andreyev, Dr Martin Benson (Gastroenterologists), Dr Clare Shaw
(Dietician), Dr Craig Carr (ITU), Ms Shelley Dolan (ITU).
The Royal Marsden NHS Foundation Trust is one of the largest comprehensive
cancer centre in Europe with over 40,000 patients from the UK and abroad seen each
year. This is a recognized training centre for Medical Oncology trainees and has
about 300 beds. It is located on two sites- Sutton and Fulham Road. I have worked as
an SpR within various Medical Oncology firms which are part of the RMH training
programme. I have been involved with seeing new patients, second opinions as well
as routine follow-ups. I have been continually involved with the busy out-patient and
in-patient ward work throughout my training.
I have gained a broad base of experience in treating all the major tumour types. My
job has involved in working at more than 1 site and also at District General Hospitals
like St Helier hospitals, Epsom and Kingston Hospital. At St Helier hospital, I
particularly enjoyed teaching medical students while doing the lung cancer clinic. I
have worked to develop my communication skills throughout my training including
two skills courses.
Throughout my period at the Royal Marsden Hospital, I gained experience in all
aspects of clinical trial work, including trial design for investigator initiated studies,
3

Dr Bhawna Sirohi’s CV
liaison with pharmaceutical companies for sponsored studies, statistical
considerations and both scientific and ethical committee approval, in addition to
active patient accrual, treatment and monitoring. I have analysed and presented
scientific and clinical data at national and international meetings. I published more
than 70 peer-reviewed papers and numerous abstracts during this period along with
oral and poster presentations throughout at international meetings. I have played an
active role in medical education and clinical management and undertaken regular
bedside and tutorial teaching of doctors, nurses and pharmacists. I have made regular
case presentations at postgraduate teachings and grand rounds.
Dec 1996-Jan 1998 Department of Medical Oncology
Tata Cancer Hospital, Parel, Mumbai, India
I worked under the supervision of Dr SH Advani and Prof PM Parikh.
Aug 1996 -Dec 1996 Medical Oncology
Indraprastha Apollo Hospital, New Delhi, India
Indraprastha Apollo Hospital is a 600 bedded hospital based in Delhi. I worked here
with Dr Rakesh Chopra as a senior registrar and gained further experience in Medical
oncology. As this was a new set-up, I trained the nurses and residents to handle and
give chemotherapy - to take care of infusion pumps, catheters, nightly feedings and
parenteral nutrition in patients receiving chemotherapy.
Gap of 3 months (May 1996- July 1996): Personal reasons
Feb 1996-Apr 1996 Medical Oncology
Rungta Hospital, Jaipur, India
I worked in this private institute as a Consultant for a short while and was in charge of
day to day care of Medical oncology patients.
Sept 1994-Jan 1996 Medical Oncology, Tata Cancer Hospital, Mumbai,
Consultants I have worked with:
Dr SH Advani (Haemato-oncology and Solid tumours); Dr T Saikia (BMT,
Lymphomas); Dr PM Parikh (Lung cancer, Gynaecologic Cancers), Dr K Nadkarni
(GI cancers, Sarcomas); Dr VR Pai (Head and Neck Cancer);Dr CN Nair (Academic
Haematology);Dr S Pai (Leukaemia and Lymphomas);Dr R Gopal (Breast,
Myeloma);
Dr P Kurkure (Paediatric tumours)
Tata Memorial hospital is a 700 bedded tertiary cancer centre which caters to the
South-East Asia draining patients from Middle-East and the Indian sub-continent.
This was a resident job, hence I stayed in hospital accommodation on the 10 th floor of
the building and the main oncology wards were on the 7 th and 11 th floor. This was
mainly for the purpose of the on-calls. During this period I gained experience in
giving chemotherapy for various malignancies, management of complications due to
chemotherapy and reporting of bone marrow slides. Besides being responsible for all
admissions and inpatient management of our 60 adult and paediatric beds, I did the
out-patient clinics daily which caters to solid tumours and haematological
malignancies, and had a daily attendance of about 60-70 patients. The training
involved rotation with the above mentioned consultants in various fields of Oncology.
4

Dr Bhawna Sirohi’s CV
July 1992-Aug 1994 Lala Lajpat Rai Medical College (LLRM),
Meerut, UP, India
During this period, I completed by DCH.
Apr 1991-Apr 1992
Intern
Prof Usha Sharma MD
Lala Lajpat Rai Medical College (LLRM),
PL Sharma Hospital
Meerut, UP, India.
PROFESSIONAL BODIES MEMBERSHIP
International
Secretary of the EBMT Nuclear Accident Committee (since 2001- )
American Society of Clinical Oncology (since 2001- )
American Society of Haematology (since 2000- )
European School of Medical Oncology (since 2006- )
Early Breast Cancer Trialists Collaborative Group (2006, 2010)
Scientific Advisor, International Myeloma Foundation (2002-2006)
Member, Acute Leukaemia Working Party, European Blood and Marrow
Transplantation (EBMT) Group (2002-2004)
Chronic Leukaemia Working Party of EBMT (Since 2002- )
Multiple Myeloma Working sub-Committee of EBMT (since 2002-2009)
Stem Cell Trialists Collaborative Group (2002-2007)
European Haematology Association (EHA) (since 2001- )
International Advisory Panel on Fungus Infections, Pfizer Limited (2001-2005)
UK
United Kingdom Myeloma Forum Clinical Trials committee (2002-2003)
British Medical Association (since 2002-2008)
British Society for Blood and Marrow Transplantation (2001-2004)
Association of Cancer Physicians, UK (since 2002-2009)
Pan-Thames purchasing BMT Consortium (since 2001-2004)
Leukaemia/Myeloma tumour working Group- South West London Cancer Network
(2002-2004)
HICC (Hospital Infection Control Committee) Royal Marsden (2001-2003)
JACIE accreditation committee, Royal Marsden (2002-2003)
Stem cell Users group (2001-2004)
5

Dr Bhawna Sirohi’s CV
Department of Health interdisciplinary Group on clinical care and service configuration
following a radiation accident (since 2008- )
Department of Health Steering Committee Member, for guidance on management of
radiation accidents (since 2008- )
India
Member, Indian Medical Association (since 1992- )
Life Member, Indian Cooperative Oncology network (ICON since 2000- )
Life Member, Indian Society of Medical and Paediatric Oncology (since 2010- )
Member, Indian Association of Palliative Care (since 2010- )
Member, Indian Society for Study of Pain (since 2010- )
Chairman, ICMR Task force for cancer guidelines on colorectal cancer
Secretary, ICMR Task force for cancer guidelines on Gastric cancer
Secretary, ICMR Task force for cancer guidelines on Multiple Myeloma
Charitable Trusts association
Committee Member: David Adams Leukaemia Fund (2007-2010)
Management committee member, Can Support (since 2010- )
Founder President, New India Cancer Charity Initiative NICCI (since 2010- )
Patron, Voice of victims Campaign (since 2011- )
Advisor- Indo-Canadian Cancer Research Foundation
Journals /Books
Editor –Indian Journal of Medical and Paediatric Oncology (IJMPO)
Editor –Health Positive
Reviewer for The Lancet, Annals of Oncology, IJMPO, Indian Journal of Cancer, JCRT
Institution –Artemis /Max
Member, Institutional review Board
Member, Independent Ethics Committee
Chairman, Care of Patients group for JCI accreditation
Member, Consumer advocacy Board
Member, Medical audit Committee (since 2010- )
Member, Antibiotics stewardship committee
6

Dr Bhawna Sirohi’s CV
Editor, Artemis e- journal
TEACHING/EDUCATION
International Collaboration
Steering secretary for Indian Cooperative Oncology Network: Phase III trial of
Erythropoietin in patients with cervical cancer
Service d’hematologie, Nantes, France: with Prof Jean-Luc Haroussaeu, International
Myeloma Foundation
International Myeloma Foundation annual think-tank (US Virgin Islands)
Secretary of the EBMT Nuclear Accident Committee: close collaboration with most
European transplant centres, ministry of defence in UK, Health protection agency,
Emergency preparedness division and Department of health. Closely involved with
training courses (RCP accredited for CPD) for haematologists, emergency physicians and
first responders across UK and Europe.
Event organisation
International Myeloma Grand round
On the 14 th June 2001, The Royal Marsden Hospital, London, hosted an unusual
event, an 'international grand round', aimed at exploring a new concept in the
treatment of multiple myeloma, 'operational cure'. The 80 invited guests included
oncologists, radiotherapists, histopathologists, representatives of the International
Myeloma Foundation, members of the press, and several myeloma patients, including
the two patients whose case histories were presented. Attendees: Prof Jean-Luc
Harousseau, Nantes France; Prof Brain Durie, UCLA, USA, Ms Susie Novis,
President IMF, Prof Greg Mundy, Texas, USA. Published in Lancet.
Bone disease Grand round 15 th March 2002 for visiting Spanish Oncologists
Prof Trevor Powles, Prof Ray Powles and Dr Mary O’ Brien
This is your Life in collaboration with BBC and RMH staff for twin Powles brothers,
2003 at the BBC studios, London.
IMF Hope, Trust and effectiveness Seminar, Royal College of Physicians, London
17th June 2003 for patients and carers.
Education session at the annual meeting of EBMT on 28 th March 2007, Lyons on
Nuclear accidents.
Grand round in collaboration with Royal Brompton Hospital (Dr Simon Davies) on
cardio toxicity and newer biologicals on 10 th July 2007, London.
EBMT Training course on the European Approach to the Medical Management
of Mass Radiation Exposure in Munich from 28 th -30 th November 2007.
Education session on nuclear accidents at the annual meeting of EBMT on 1 st April
2008, Florence, Italy.
7

Dr Bhawna Sirohi’s CV
Education session on nuclear accidents at the annual meeting of EBMT on 1 st April
2009, Gotheborg, Sweden.
Education session on nuclear accidents at the annual meeting of EBMT on 23rd
March 2010, Vienna, Austria
Onco-Cardiology CME, at Max Cancer Centre in collaboration with ISMPO, ICO,
with Prof Thomas Suter 24 th April 2010.
Breast Cancer Survivors workshop. Max Cancer Centre. 29 th May 2010
First Brinker awardees meeting in New Delhi by NICCI on 13 th November 2010
with the launch of NICCI at the British ambassador’s house.
24 th ICON meeting in New Delhi on 11-13 th March 2011
Education session on nuclear accidents at the annual meeting of EBMT on 5 th April
2011, Paris, France.
Education session on nuclear accidents at the annual meeting of EBMT on 3 rd April
2012, Geneva.
First European training workshop on radiation/nuclear accidents , 4 th April 2012,
Geneva.
UAE Cancer congress, Organsiing committee and Program coordinator for the GI
session, 11-13 th Oct 2012, Dubai
TMH-WCI conference, Organising secretary 19 th -21 st Oct 2012 at Tata Memorial
Hospital, Mumbai
Education session on nuclear accidents at the annual meeting of EBMT on 10 th April
2013, London, UK
Indian Cancer congress 2013, Organising committee and anchor for the breast group.
Noida
28 th ICON 2013, Organising committee
Teaching:
I have always greatly enjoyed teaching, and have been involved in the undergraduate
or post-graduate teaching programme
1998 to 2007 Weekly teaching sessions for medical students and SHOs
1999-2001 FRCR Seminars in Oncology Course
1999-2002 Haematology Study Day: for SpRs
8

Dr Bhawna Sirohi’s CV
1999- 2007: Teaching of pharmacists and at nursing college of Royal
Marsden Hospital
2004 Teaching Medical students at St Helier hospital once a week
2008 Teaching medical students /SpRs journal club at Addenbrookes
2009 Training nurses, pharmacists and junior doctors in cancer care,
chemotherapy administration
Courses attended
14 th October 2008 Advanced Resuscitation training
17 th January 2008 ICH-GCP update course
16 th -20 th July 2007 Kings Fund Management course for SpRs
1 st -2 nd Mar 2007 Training course for EBMT members: “manage nuclear
accidents”
27 th Feb 2007 Physicians as Educators “On job teaching” RCP course
8 th May 2006 RMH Communications and skills day
14 th Oct 2005 Ethics and Communication Skills Day, Birbeck College,
London
10 th Feb 2005 Good clinical Practice and the EU directive (ICH/GCP
training)
1999 ASCO Clinical Trials Workshop, Flims, Switzerland
MANAGEMENT EXPERIENCE
Setting up a new unit
I was involved with setting up of the haemato-oncology unit from the beginning at
Parkside Oncology clinic with Prof Ray Powles. We celebrated 5 years in January
2009. I helped set up the auto transplant programme which included setting up the
infrastructure, basic training and education of the nurses, getting EBMT accreditation
for the unit, setting up unit guidelines, treatment protocols and SOPs.
I also set up the medical oncology at Max Cancer centre Saket and Patparganj, New
Delhi and was involved from initial stages. I helped develop the concept of
specialised oncology nursing and onco-pharmacy with the use of admixture lab up to
international standards.
Awards and Distinctions
I was nominated for the Royal Marsden award for excellence by the General Manager
for the rare cancer division Ms Lucie Waters in 2002. This was for my outstanding
contribution to enhancing the trusts reputation in operational research and education.
Nominated to be a committee member on David Adams Leukaemia Fund in 2008.
Nominated to be on the Management Committee of Can Support in 2010.
9

Dr Bhawna Sirohi’s CV
Elected to the Executive committee of Indian Society of Medical and Paediatric
Oncology (2011-2015)
Elected to the Management committee of Indian Cooperative Oncology Network (2010-
2012).
Nominated as a Member, Expert Panel NDTV in 2011.
Nominated to be Patron for Voice of Tobacco victims in 2011.
Invited to Guest edit the book on Cancer by NDTV.
Invited by Elsevier to be Guest Editor (with Dr Samirun Nundy) for ECAB – adjuvant
and neoadjuvant chemotherapy in GI cancers.
Received the Women’s Cancer Initiative award in 2011 for charity work through
NICCI.
Received the LBF Visionary award for excellence in 2011.
Charity /National service
I have in the past been closely involved with the following charities and have helped
raise money for the Royal Marsden hospital through these: David Adams Leukaemia
Fund, Bud Flanagan Leukaemia Fund, Johnstone Britten Myeloma Fund, Fergus
MacLay database fund.
I was nominated to the management committee of Can support, a palliative care
organisation in NCR in 2010
I have set up NICCI- New India Cancer Charity Initiative to do clinical screening in
villages in UP and also train Aaganwadi and ASHA workers in early signs of cancer
and healthy lifestyle. As part of this, I also do cancer awareness talks within NCR in
schools, colleges, corporate and resident welfare organisations.
I am a patron of the voice of tobacco victims (VoTV) campaign.
2011 - Screening camps /health awareness talks in Meerut, Daurala, New Delhi,
Rewari, Dwarka, noida, Ghaziabad, Resident welfare associations of chittranjan park,
saket and schools around Delhi and Meerut
2012- Screening camps /health awareness talks in Bahadurgarh, Mahendragarh,
Rewari, Kota (thamblou), Rajasthan
Sept and Oct 2012- Involved with initial setting up of cancer registry in Rawatbhatta
and Sangrur
2012- Initial setting up plans of TMH, Chandigarh
International Committees
Throughout my period at the Royal Marsden since 2002, I have actively continued to
participate in the EBMT nuclear accident committee in my role as the secretary
collaboration with Department of health, Health protection agency, emergency
preparedness division and ministry of defence, IAEA and WHO. We have developed
a pocket guide for EBMT centres for managing patients within first 48 hours after
radiation exposure. I have organised training course (RCP CPD accredited) for NHS
10

Dr Bhawna Sirohi’s CV
trusts in UK in close collaboration with the Department of health. We are now in the
process of organising a one-day European training course in London in April 2013.
I have also made major contribution to the International Myeloma foundation
scientific meetings in my role as their scientific advisor. I was closely involved with
the workshop organised in Paris from 3 rd -8 th May 2011.
Course
Kings fund Management course in July 2007.
Service planning
UK
1. Funding requests for interventions outside national or local guidelines were coordinated
by the service planning department. I had regular dialogue with this
department and was responsible for a number of formal requests for high-cost funding
that required review by the local primary care trust.
2. In order to facilitate clinical governance, I have been involved in working closely
with senior pharmacists to edit and create a number of different chemotherapy
protocols and proformas
3. I have actively participated in the site specific group meetings for pancreatic cancer
and skin cancer for the Anglia cancer network.
4. I have been involved with pancreatic cancer centre review by specialised
commissioning group in drafting a report at the Royal Marsden.
India
1. Building up a referral network through educational activities and screening camps
in and around Delhi
2. Setting up DNB in a private institute
3. Setting up site-specific approach within the clinics
4. Optimising palliative care and pain control
5. Ongoing audits for 30-day chemotherapy mortality, central lines, infections and
adherence to protocols.
6. Patient information literature
Meetings attended for CPD
I have attended the ASCO (May), ASH (Dec), and EBMT (March) meetings almost
every year since 1998 and have previously presented at these meetings (oral, poster,
poster discussion or education sessions) consistently.
I also attend the Indian Cooperative oncology network and ISMPO meeting alternate
years. I have attended San Antonio Breast meeting in 2007, 2009 and have attended
dedicated breast cancer meeting (IBCC, Paris). I attended ESMO Lugano in 2008.
I have attended the Oxford overview EBCTCG in 2006 (from Royal Marsden) and
2010 (20th -23rd Sept from Delhi), 2012 (from TMH).
ORAL PRESENTATIONS:
1. Burkitts Lymphoma - A TMH experience at XXXVI Annual Conference of
ISHBT (Indian Society of Haematology and Blood Transfusion) 1995, Bangalore.
2. CNS directed chemotherapy in children less than or equal to 3 years of age: Use
of G-CSF in maintaining dose intensity- in Feb 1997 at Madurai in ISMPO
(Indian Society of Medical and Paediatric Oncology).
11

Dr Bhawna Sirohi’s CV
3. Low incidence of cardio toxicity following daunomycin and doxorubicin at a 10
year follow-up in March 1997 at Annual Conference of Bombay Haematology
group at Bombay
4. Single centre evaluation of long term follow up of autologous stem cell
transplantation for first remission adult ALL: potential for cure without excessive
toxicity; Annual meeting of European Bone Marrow Transplantation (EBMT)
Group, Innsbruck 6 th March 2000.
5. Central nervous system relapse after stem cell transplantation (SCT) for acute
leukaemia beyond first remission; Annual meeting of EBMT Group, Innsbruck 6 th
March, 2000.
6. CNS relapse after auto- and allo- stem cell transplant (SCT) for acute leukaemia
beyond first CR. 5 th Annual Meeting of the European Haematology Association,
June 2000.
7. High-dose mephalan with auto-transplantation in Myeloma patients with severe
renal dysfunction (GFR

Dr Bhawna Sirohi’s CV
18. Results of randomised, cross over study comparing pegylated interferon with
interferon-alpha2b in patients with myeloma,8 th Congress of EHA, Lyons, France
15 th June 2003
19. Serum free light chain assessment in myeloma patients in complete remission, 29 th
EBMT Annual Meeting, Istanbul, Turkey, 21 st July 2003
20. Randomised, two-period cross over study comparing quality of life and toxicity of
pegylated interferon with interferon-alpha2b in patients with myeloma, 29th
EBMT Annual Meeting, Istanbul, Turkey, 22nd July 2003.
21. Effect of human growth hormone in haemato-oncology patients receiving
intensive chemotherapy- a double-blind randomised placebo controlled trial , 23 rd
joint meeting of British Endocrine societies , Brighton, 23 rd March 2004.
22. Long term use of Capecitabine in patients with locally recurrent or metastatic
breast cancer: concept for metronomic chemotherapy, ESMO Lugano 2008
POSTER PRESENTATIONS:
1. A Phase I-II study evaluating the feasibility of acute lymphoblastic leukaemiatype
intensive consolidation chemotherapy (UKALL XA) after initial C-VAMP
and high-dose melphalan auto transplantation at VIIth International Multiple
Myeloma Workshop, Stockholm, 2nd September 1999
2. The implications of compromised renal function at the time of presentation: A
single centre study of 251 patients. Annual Meeting of American society of
Haematology, New Orleans, December 7 1999.
3. Light chain disease (LCD): A different form of myeloma compared with IgG
disease. Annual Meeting of American society of Haematology, New Orleans,
December 7 1999.
4. High dose chemotherapy and autologous transplantation in myeloma patients
aged 65 years and over: A case control comparison with younger patients. Annual
Meeting of American society of Haematology, New Orleans, December 7, 1999.
5. A comparison of kinetics of paraprotein clearance: Rapid decline of paraprotein
after high dose melphalan (HDM) versus infusional chemotherapy (IC) in
previously untreated patients with IgG multiple myeloma. Annual meeting of
EBMT Group, Innsbruck 6 h March, 2000.
6. High dose chemotherapy (HDT) and autologous transplantation in myeloma
patients aged 65 years and over: A case control comparison with younger patients.
Annual meeting of EBMT Group, Innsbruck 6 th March, 2000.
7. Glomerular filtration rate (GFR) as a surrogate marker for transplant related
toxicity and overall outcome in patients of multiple myeloma (MM)
homogenously treated with high dose melphalan (HDM) 200mg/m 2 . Annual
meeting of EBMT Group, Innsbruck 6 th March, 2000.
8. Bence-Jones (BJ) Myeloma: A different form of myeloma compared to IgG and
IgA myeloma. Annual meeting of EBMT Group, Innsbruck 6 th March, 2000.
9. The implication of compromised and normal renal function at presentation in
myeloma. Annual meeting of EBMT Group, Innsbruck 6 th March, 2000.
10. Kinetics of paraprotein clearance: rapid decline of paraprotein after high-dose
melphalan (HDM) compared to infusional chemotherapy in previously untreated
patients with IgG myeloma. 5 th Annual Meeting of the European Haematology
Association. 2000:
11. Glomerular filtration rate as a surrogate marker for transplant-related toxicity and
overall outcome in patients with multiple myeloma homogenously treated with
13

Dr Bhawna Sirohi’s CV
high-dose melphalan. 5 th Annual Meeting of the European Haematology
Association. 2000:
12. High-dose therapy and auto transplantation in myeloma patients aged 65 years
and over: A case control comparison with younger patients. 5 th Annual Meeting of
the European Haematology Association. 2000:
13. Compromised renal function at presentation in myeloma – similar outcome in
patients who receive high-dose therapy (HDT): A single centre study of 251
previously untreated patients. British Society of Haematology, Bournemouth,
2000.
14. Bence Jones (BJ) myeloma: A distinct entity compared to IgG and IgA myeloma.
British Society of Haematology, Bournemouth, 2000.
15. Central nervous system relapses after stem cell transplantation (SCT) for acute
leukaemia beyond first remission. British Society of Haematology, Bournemouth,
2000.
16. Central nervous system relapse after stem cell transplantation for acute
leukaemia beyond first remission, Leukaemia 2000; Houston, 6 th September 2000
17. Single centre evaluation of autologous stem cell transplantation in first remission
followed by maintenance chemotherapy in patients with acute lymphoblastic
leukaemia, Leukaemia 2000; Houston, 6 th September 2000
18. High-dose melphalan and auto transplantation in myeloma patients with severe
renal dysfunction (creatinine clearance 20 ml/min/m 2 ): High incidence of atrial
fibrillation and treatment-related mortality. Annual Meeting of American society
of Haematology, San Francisco, 5 th December 2000
19. Central nervous system relapses in acute leukaemia patients transplanted beyond
the first remission. Annual Meeting of American society of Haematology, San
Francisco, 5 th December 2000
23. Spectrum of fungal infections in patients with haematological malignancies in the
last 5 years: Royal Marsden experience. Annual meeting of EBMT Group, March,
2001.
24. Early response to infusional chemotherapy is an independent prognostic factor in
newly diagnosed IgG and IgA multiple myeloma. Annual meeting of EBMT
Group, March, 2001.
25. Maximal response to infusional chemotherapy prior to auto transplantation
influences outcome of patients with newly-diagnosed multiple myeloma. Annual
meeting of EBMT Group, March, 2001.
26. High Dose melphalan and auto transplantation in myeloma patients with severe
renal dysfunction: high incidence of atrial fibrillation and treatment-related
mortality. Annual meeting of EBMT Group, March, 2001.
27. Role of Defibrotide (Dt) and Therapeutic Plasma Exchange (TPE) in the
management of transplant associated thrombotic Thrombocytopenic
Purpura/Hemolytic Uremic Syndrome (TTP/HUS): a single centre Experience.
Annual meeting of EBMT Group, March, 2001.
28. Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving
sequential therapy: the need to regard these immunologic subtypes as separate
disease entities with specific prognostic criteria. Annual meeting of EBMT Group,
March, 2001.
20. High-Dose Melphalan with Autologous Peripheral Stem Cell Rescue in Myeloma
Patients with Severe Renal Dysfunction (Creatinine Clearance

Dr Bhawna Sirohi’s CV
High Incidence of Atrial Fibrillation and Treatment-Related Mortality; British
society for Haematology, Harrogate , 23 rd April 2001
21. Early response to infusional chemotherapy is an independent prognostic marker
in newly-diagnosed IgG and IgA myeloma, British society for Haematology,
Harrogate, 24 th April 2001
22. High-Dose Melphalan with Autologous Peripheral Stem Cell Rescue in Myeloma
Patients with Severe Renal Dysfunction (Creatinine Clearance

Dr Bhawna Sirohi’s CV
35. Implications of impaired renal function at the time of initiation of infusional
chemotherapy including cyclophosphomide (C-VAMP) in patients with newlydiagnosed
myeloma. 28 th EBMT Annual Meeting, Montreux, Switzerland. 26 th
March 2002.
36. Early high-resolution computed tomography (HRCT) scans allow prompt
diagnosis and efficacious treatment of invasive pulmonary aspergillosis (IPA) in
immunocompromised patients with haematologic malignancies. 28 th EBMT
Annual Meeting, Montreux, Switzerland. 27 th March 2002.
37. Clinical implications and consequences of leukapheresis to reduce tumour burden
in newly-diagnosed patients with hyperleukocytosis (HL) and acute myeloid
leukaemia. 28 th EBMT Annual Meeting, Montreux, Switzerland. 26 th March
2002.
38. Allogeneic transplantation with melphalan-total body irradiation from HLAidentical
siblings for AML in first remission: higher relapse rates with marrowderived
stem cell grafts compared to blood despite similar chronic graft-versushost
disease. 28 th EBMT Annual Meeting, Montreux, Switzerland. 27 th March
2002.
39. Administration of weekly cyclophosphamide as part of infusional induction
chemotherapy (C-VAMP) does not affect subsequent peripheral blood stem cell
collection in patients with myeloma. 28 th EBMT Annual Meeting, Montreux,
Switzerland. 26 th March 2002.
40. 20-year follow-up of allogeneic bone marrow transplantation with
cyclophosphamide - TBI and cyclosporine for acute myeloid leukaemia in first
complete remission. 28 th EBMT Annual Meeting, Montreux, Switzerland. 26 th
March 2002.
41. Does the Number of Infused CD34 Cells Affect the Long-Term Outcome of
Myeloma Patients Treated with High-Dose Melphalan and Auto transplantation?
7 th Congress of EHA, 6-9 th June 2002, Florence, Italy.
42. The Addition of Weekly Cyclosphosphamide to Infusional Induction
Chemotherapy (Vincristine, Doxorubicin, and Methylprednisolone) Does Not
Affect Subsequent Stem Cell Collection in Patients with Myeloma. 7 th Congress
of EHA, 6-9 th June 2002, Florence, Italy.
43. Bone Marrow or Peripheral Blood Stem Cell Auto transplantation for AML in
First Remission? A Matched-Pair Analysis from the Royal Marsden Hospital and
the European Blood and Marrow Transplant Group (EBMT). 7 th Congress of
EHA, 6-9 th June 2002, Florence, Italy.
44. Early high resolution CT (HRCT) scans allow for prompt diagnosis and
efficacious treatment of invasive pulmonary aspergillosis (IPA) in immunocompromised
patients with haematologic malignancies. 7 th Congress of EHA, 6-
9 th June 2002, Florence, Italy.
45. Implications of impaired renal function at the time of initiation of infusional
chemotherapy (C-VAMP) in patients with newly-diagnosed myeloma. 7 th
Congress of EHA, 6-9 th June 2002, Florence, Italy.
46. Clinical implications and consequences of leukapheresis to reduce tumour burden
in newly-diagnosed patients with hyperleukocytosis (HL) and acute myeloid
leukaemia. Annual meeting of British Society of Haematology, Brighton, 2002,
47. Outcome of auto transplantation in 118 adult acute myeloid leukaemia patients in
first complete remission: impact of consolidation chemotherapy (CC). Annual
meeting of British Society of Haematology, Brighton, 2002,
16

Dr Bhawna Sirohi’s CV
48. Implication of impaired renal function at the time of initiation of infusional
chemotherapy including cyclophosphamide (C-VAMP) in patients with newly
diagnosed myeloma. Annual meeting of British Society of Haematology,
Brighton, 2002,
49. Relapse following complete remission outcome predictors in patients with
secretory myeloma. ). Annual meeting of British Society of Haematology,
Brighton, 2002,
50. Administration of weekly cyclophosphamide as part of infusional induction
chemotherapy (C-VAMP) does not affect subsequent peripheral blood stem cell
collection in patients with myeloma. ). Annual meeting of British Society of
Haematology, Brighton, 2002,
51. 200 mg/m2 Melphalan (HDM200) and Salvage Auto transplantation in Myeloma
Patients Relapsing after a Preceding Autograft. Annual meeting of American
society of Haematologists, Philadelphia, 9th December 2002.
52. Adult Patients with De Novo Acute Myeloid Leukaemia Receiving High-Dose
Cytarabine-Based Induction Chemotherapy: A Single Centre Study of 136
Patients. Annual meeting of American society of Haematologists, 2003
53. 10-Year Survival in Myeloma: Have the Results Improved in the Last Decade?
Annual meeting of American society of Haematologists, 2003
54. Significance of Length of First Complete Remission (CR) in Newly-Diagnosed
Secretory Patients with Myeloma: A Study of 131 with a Minimum Follow-Up of
5 Years. Annual meeting of American society of Haematologists, 2003
55. Primary Refractory (PRef) Myeloma: Recommendations for Treatment. Annual
meeting of American society of Haematologists, 2003
56. Prognostic Significance of Immunoparesis (Ip) at Diagnosis and Continued
Complete Remission (CR) in Newly Diagnosed Secretory Myeloma Patients.
Session Type: Annual meeting of American society of Haematologists, 2003
57. Effect of Human Growth Hormone in Haemato-Oncology Patients Receiving
Intensive Chemotherapy. A Double Blind Randomized, Placebo-Controlled
Study. Annual meeting of American society of Haematologists, 2003
58. 200 mg/m2 Melphalan and Autograft Followed by Maintenance Chemotherapy
with 6-Mercaptopurine (6MP), Methotrexate (MTX), and Vincristine-Prednisone
(VP) in 65 First Remission Acute Lymphoblastic Leukaemia Patients. Annual
meeting of American society of Haematologists, 2003
59. 2 posters at EBMT 2004
60. Early response to platinum-based chemotherapy in non small cell lung cancer
(NSCLC) predicts survival , ASCO 2005
61. Use of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P) with or without
Rituximab in Relapsed and Refractory Patients with Diffuse Large B Cell
Lymphoma, ASH 2005.
62. Retrospective study of Gemcitabine, Cisplatin and Methylprednisolone (GEM-P)
with or without Rituximab in Relapsed and Refractory Patients with Diffuse Large
B Cell Lymphoma (DLBCL). EBMT 2006
63. Long-term outcome of high-dose chemotherapy and autologous stem cell
transplantation in relapsed/refractory Hodgkin's disease: A cohort of 199 pts from
Royal Marsden Hospital, ASCO 2006
64. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid
and liver function tests in metastatic neuroendocrine carcinomas of the
gastroenteropancreatic tract, ASCO 2006
17

Dr Bhawna Sirohi’s CV
65. The role of maintenance chemotherapy after auto transplantation for acute
lymphoblastic leukaemia in first remission: single-centre experience of 100
patients. ASH 2007
66. Use of platinum-based chemotherapy in patients with triple negative breast
cancer, ASCO 2008
67. Trans-Atlantic Consensus on the Medical Management of Radiation Accident
Victims, ASH 2008
RESEARCH:
I have had the opportunity to be a chief investigator and principal investigator for
various clinical trials. I have also helped design and set up clinical trials from
initiation to recruitment.
Chief Investigator
Phase-3 multi-centre, international, randomised trial evaluating Bevacizumab as
adjuvant therapy following resection of cutaneous melanoma (submitted for ASCO
2009).
Principal investigator
Study A6181170: Phase 3 randomised trial comparing Sunitinib versus Sorafenib in
patients with advanced hepatocellular carcinoma trial
A phase II study of PTK787 in metastatic melanoma patients
A randomised double-blind Phase III trial comparing addition of STA-4783 to
Paclitaxel in patients with metastatic melanoma.
An Open-Label, Pharmacokinetic Study of the Safety and Tolerability of Pazopanib
in Combination with FOLFOX 6 or CapeOx in Subjects with Colorectal Cancer
Trials at Artemis:
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Phase 3 Study of
Denosumab as Adjuvant Treatment for Women with Early-Stage Breast Cancer at
High Risk of Recurrence (D-CARE)
Phase II Study Of Weekly Cisplatin & Paclitaxel Plus Cetuximab As Induction
Therapy In Patients With Advanced Squamous Cell Carcinoma Of The Head And
Neck (SCCHN).
An open-label randomized comparative multicentre study to assess safety and
efficacy of BIOMAb-EGFR TM (Nimotuzumab) in combination with chemotherapy
versus chemotherapy alone in the treatment of patients with stage IIIb / IV non small
cell lung cancer (NSCLC).
Retrospective review of data for breast cancer patients
Myeloma Trials
1871 A phase II trial comparing the quality of life, tolerability and toxicity of PEG
Intron with INTRON A in patients with myeloma.
18

Dr Bhawna Sirohi’s CV
2048 A randomised comparison of the effect of maintaining haemoglobin levels
with weekly Eprex or with conventional anaemia management in subjects with
multiple myeloma undergoing chemotherapy
2122 A pilot study of Zometa in patients with multiple myeloma and stable partial
remission/early relapse following complete remission.
2123 Light Chain Assay in Multiple Myeloma patients in CR
2127 An international, non-comparative, open-label studies of PS-341 versus high
dose dexamethasone in patients with relapsed or refractory multiple myeloma.
2126 An international, non-comparative, open-label study of PS-341 administered to
patients with myeloma who experienced relapsed or progressive disease after having
received at least four previous treatment regimes or experienced progressive disease
after receiving dexamethasone in Millennium protocol M34101-039
1899 A phase I open-study of the safety, tolerance, pharmacokinetics, antigenicity
and efficacy of a single intravenous dose of AHM followed by multiple doses of
intravenous AHM in subjects with multiple Myeloma.
Infection Trials
1930 An open-label, non-comparative study of FK463 for the treatment of Invasive
Candidiasis
1931 An open-label, non-comparative study of FK463 for the treatment of invasive
aspergillosis
2082 An open-label non-comparative study of the safety and efficacy of intravenous
anidulafungin plus ambisome as a treatment for invasive aspergillosis
2218: Caspofungin as antifungal prophylaxis in patients receiving all-SCT.
1450 A prospectively randomised, double blind comparative multi-centre study to
evaluate efficacy and safety of Nyotran and Amphotericin B for empirical
antifungal treatment in neutropenic patients
1874 A phase II study to determine the safety profile, the maximum tolerated dose
and PK's of FK463 for prophylaxis of fungal infections in adult patients undergoing a
bone marrow or PBSC transplant FK463 for prophylaxis
Transplant Trials
1812 A pilot study of upfront high-dose melphalan with autologous stem cell rescue
in newly diagnosed patients with multiple myeloma.
2084 Defibrotide for the treatment of hepatic veno-occlusive disease after stem cell
transplantation (DF-VOD Trial)
2083 Phase II study of low intensity non-myeloablative allograft following high
dose Melphalan with autologous stem cell support in myeloma patients with sibling
donors (UKMF).
1901 A phase I pilot, open-labelled, single-centre multiple ascending dose study to
evaluate the pharmacokinetics and effect on administration of STI-571 on post
allogeneic stem cell transplant myeloid recovery in patients with haematological
malignancies.
1625 A multi-centre, open centre, non-randomised phase I-II study to investigate
mobilisation by a combination of Ancestim (r-metHuSCF) and Filgrastim (rmetHuGCSF)
Lenograstim versus Filgrastim
Leukaemia Trails
19

Dr Bhawna Sirohi’s CV
2161 An open-label study to find out if ZARNESTRA/R115777 treatment is
effective and safe in the treatment of patients with High Risk Myelodysplastic
Syndrome (MDS).
2128 A randomised trial of human growth Hormone (hGH) versus placebo in
haemato-oncology patients treated intensively for prevention of loss of muscle mass
and weight
MRS Spectroscopy in new patients with leukaemia
1395 A multiple ascending dose study evaluating the safety and efficacy of
intravenous infusion of LF 08-299 administered as first line treatment in combination
with corticosteroids in patients with acute GVHD. Fournier.
Urology Trials
PSMA DNA vaccine in prostate cancer: COREC submission and sponsorship issues
AMG 114 trial - Treatment of Anaemia in Subjects with Non-myeloid Malignancies:
Local R & D submission
Lymphoma /GI
1246: A retrospective and prospective assessment of toxicity and outcome of high
dose consolidation chemotherapy in high grade Non-Hodgkin’s lymphoma and
Hodgkin’s disease.
2656 A retrospective review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P)
with or without Rituximab in patients with relapsed/refractory diffuse large B-cell
lymphoma (DLBCL).
2655 A retrospective study of toxicity and outcome of high dose chemotherapy with
autologous stem cell transplant in patients with Hodgkin Lymphoma (HL).
2657 A retrospective study of toxicity and outcome of high dose chemotherapy with
autologous stem cell transplant in patients with Non-Hodgkin Lymphoma (NHL).
LIFE: Phase III randomsied trial - First-line 5-Fluorouracil Regimens With or
Without Oxaliplatin in Advanced Colorectal Cancer
Ovarian cancer
Impact of second line chemotherapy with a platinum or non-platinum regimen in
partially platinum-sensitive and platinum sensitive recurrent epithelial ovarian,
fallopian tube and primary peritoneal cancer
Breast Cancer
ATHENA: International multi-centre trial with the use of bevacizumab and
chemotherapy in patients with newly diagnosed metastatic breast cancer. : COREC
submission and participation in MREC approval process along with presentation to
the Cambridge REC on behalf of the chief investigator Prof Ian Smith.
INVITED LECTURES /SESSIONS
1. Spectrum of fungal infections: Marsden experience. EORTC meeting, Nijmegen,
Netherlands 14 th October 1998 ,
2. Bone Marrow Transplantation -International Youth Science Forum, Bud
Flanagan. 3 rd August 1999.
3. “Towards curing Myeloma”; Tata Memorial Hospital, Mumbai 7 th October 1999
4. Myeloma and renal failure –therapeutic implications, SMS Medical College,
Jaipur ; 11 th October 1999
20

Dr Bhawna Sirohi’s CV
5. Principles of stem cell transplantation- Indraprastha Apollo Hospital, New Delhi,
14 th October 1999
6. State of art therapy in multiple myeloma – Indian Medical Association, Meerut ,
15 th October 1999
7. BMT in Myeloma, Regional Study Day in Haematology on Bone Marrow
Transplantation, London, 25 th November 1999.
8. Use of diflucan in Haematological Malignancies, Pfizer global perception
meeting, Paris, March 2000
9. Fungal infections in patients with haematological malignancies: RMH experience,
National Haematology meeting, Thessaloniki, Greece, 17 th November 2000.
10. Stem cell transplantation in myeloma , Armed Forces Medical college, Pune,
December 2000
11. High-dose treatment in Acute Lymphoblastic Leukaemia, 4 th UAE International
cancer congress, Abu Dhabi, 30 th January 2001
12. Current Management of Myeloma, 4 th UAE International cancer congress, Abu
Dhabi, 30 th January 2001
13. Allogeneic peripheral blood stem cell transplantation, 4 th UAE International
cancer congress, Abu Dhabi, 31 st January 2001
14. Allogeneic stem cell transplantation : marrow versus peripheral blood stem cells ,
Acute Leukaemia Working Party meeting, Sestri Levante, Genoa, 24 th February,
2001
15. International Myeloma Grand round: Case History presentation, Royal Marsden
Hospital, London, 14 June 2001.
16. Autologous Transplantation in Myeloma: Marsden experience, Xth Annual course
in Haematology, London, 8 th November, 2001
17. Cancer awareness-global scenario. Indian cooperative Oncology Network, Port
Blair, India, 12 th January 2002.
18. Erythropoietin and anaemia: Indian cooperative Oncology Network, Port Blair,
India, 13 th January 2002.
19. Emerging concepts in Myeloma therapy – APICON, Chennai, India, 16 th January
2002
20. 15 th February 2002 Myeloma and high dose chemotherapy Cripps lecture room
RMH
21. Fungal infections in patients with haematological malignancies , Pharmacy
Summit, New Orleans , 13 April 2002
22. Review of Amphocil tolerability audit, Pharmacy Summit, New Orleans , 13 April
2002
23. Multiple Myeloma-renal outcomes , South West Thames Renal and Transplant
Unit, St Helier’s Hospital, 8 th March 2002
24. Allogeneic stem cell transplantation- current scenario; National CME on
Haematopoietic Stem cell Transplantation- 2002, New Delhi, 31 st March 2002
25. Auto transplantation in myeloma: single centre experience: International
Myeloma foundation think-tank meeting, US Virgin Islands, St Johns Retreat, 11-
15 May 2002.
26. High-dose treatment in myeloma- is better? ; South Thames Haematology
Specialist committee, BMA House, 17 July 2002
27. Growth hormone: Marsden randomised study , Munich, Sept 2002
28. Current place of auto grafting in acute leukaemia ; Regional Study Day for
Haematologists , 28 November 2002
21

Dr Bhawna Sirohi’s CV
29. Myeloma Update ; Regional Study Day for Haematologists , London, 28
November 2002
30. Renal disease in Myeloma, Thames Myeloma Audit, Middlesex, 20 th March 2003
31. Auto transplantation in Myeloma: Issues? Golden Jubilee of International CME
on Transplantation, New Delhi, March 30 2003.
32. Newer agents in Myeloma, IMF Hope Trust and Effectiveness for Myeloma
Patients, June 17, 2003
33. New treatments for myeloma, PCT day, Parkside cancer Centre , 1 st Feb 2005
34. Use of monoclonal antibodies in NHL, Multidisciplinary study day, St Raphael’s
hospice, 1 st June 2006.
35. Nuclear accidents: what have we learned? Role of EBMT. Gulhane Military
Medical Academy, Ankara, Turkey, 24 th Nov 2006
36. Pre-requisites for designation of hospitals to participate in management of
radiation accidents , Munich 30 th Nov 2007
37. Breast Unit Meeting, Royal Marsden Hospital, Platinum’s in triple negative breast
cancer, 23 rd November 2007
38. Breast cancer and pregnancy: complex care issues. National study day for nurses,
17 th September 2007.
39. LEAP :RMH experience, Advisory board, London, 3 rd December 2007
40. Lapatinib in metastatic breast cancer, Edinburgh, 29 th January 2008
41. EBMT preparedness for radiation accidents, Tandem BMT meeting , San Diego,
14 th February 2008
42. Allogeneic transplantation in 48 patients who received accidental irradiation, 1 st
April 2008, Florence, EBMT 2008
43. Use of Tyrosine kinase inhibitors in metastatic breast cancer, 19 th Indian
Cooperative Oncology Network meeting, 21 st September 2008, India
44. Global (US/European) consensus on management of radiation accident victims,
Cologne, Germany , 25 th September 2008
45. Targeted therapy, West Anglia nurses study day. September 30, 2008.
Addenbrookes hospital, Cambridge.
46. Breast and cervical cancer awareness: Public health awareness event at
Swaminarayan temple, Neasden, London 11th October 2008
47. Anglia Network Tyverb launch meeting: Lapatinib in principle and practice:
Insights from clinical experience – what does the evidence tell us? 21 st October
2008, Bedford
48. Oncologic emergencies : Cambridge medical seminars, Churchill College,
Cambridge, 22 nd November 2008
49. Gene expression profiling in breast cancer. ISMPO annual meeting, Srinagar, 24 th
October 2009
50. ISMPO annual meeting, Srinagar, 24 th October 2009
51. Handling of cytotoxic drugs and devices and Cross infection control. Nurses
training workshop, New Delhi. 3 rd and 4 th November 2009
52. Art of Caring. Max Cancer Centre, New Delhi, 8 th December 2009.
53. Haematological and Oncologic emergencies, Asia Pacific Critical Care Meeting,
New Delhi, 6 th December 2009
54. Mechanisms of Her 2 resistance. OASIS meeting, New Delhi and Bangalore 28 th
and 29 th Oct 2009
55. Importance of Living will- dying with dignity. Cansupprt/IRCH Foundation
course. 20 th January 2010
22

Dr Bhawna Sirohi’s CV
56. Role of physicians in Cancer diagnosis and staging. PROMOTE India,
Hyderabad, 23 rd January 2010.
57. Cancer of oesophagus. Max Cancer Centre GI forum. Noida. 2 nd February 2010
58. Hyperleukocytosis in leukaemia patients. Mortality Meet, Max Healthcare. 12 th
January 2010
59. Targeted therapy in MBC: hits and misses, Bangalore. 5 th Feb 2010
60. Gene Expression Signatures of PI3K Signaling Are Associated with Low ER
Levels and the Luminal B Subtype in Breast Cancer Cell Lines and Human
Tumours, and in Patients Predicts Poor Outcome (Creighton CJ et al ). San
Antonio 2009 revisited, Mumbai, 14th Feb 2010
61. Phase III Trial Comparing ACT with ACTH with TCH in Her2neu Positive
Early Breast Cancer Patients: BCIRG 006 Study (Slamon D et al) San Antonio
2009 revisited, Mumbai, 14th Feb 2010.
62. Breast Cancer. ICON Meeting Kolkata. 20 th Feb 2010
63. Professional conduct, Etiquette and Ethics- MCI. Max Healthcare, New Delhi, 22
Feb 2010
64. Cancer awareness. International Women’s day, Chitranjan Park, New Delhi, 8 th
March 2010
65. End of Life Care for patients with advanced cancer. Mortality Meeting. Max
Healthcare, New Delhi, 9 th March 2010.
66. METREPOL use in radiation accidents. Department of Health Meeting, London,
12 th March 2010
67. Cancer awareness, Roorkee. 14 th March 2010
68. UK planning in case of a radiation accident. EBMT Education session. Vienna.
23 rd March 2010
69. Care of venous access devices. CVAD refresher course. New Delhi. 17 th April
2010
70. Case based discussion. Onco-Cardiology CME. New Delhi, 24 th April 2010
71. Hyperleukocytosis and Hyperviscosity. Haemato-Oncology CME, Max Cancer
Centre, New Delhi, 15 th May 2010.
72. Lymphadenopathy- approach to diagnosis. PROMOTE CME. Meerut, 23 rd May
2010
73. Tobacco and Cancers. Tobacco Cessation Workshop. New Delhi. 3 rd June 2010.
74. Chemotherapy trials- first line and beyond in advanced ovarian cancer. Best of
ASCO, Hyderabad, 10 th July 2010
75. Re-biopsy at the time of relapse in patients with advanced breast cancer? Best of
ASCO, Hyderabad, 10 th July 2010
76. Cancer management in the 21 st century. Artemis Cancer Centre. Gurgaon. 21 st
August 2010
77. Cancer awareness. JCI Karnal. 12 th September 2010
78. Bone pain and Cancer. PromOTE Pain-ONCO CAP CME, New Delhi, 26th
September, 2010.
79. Phase II/III clinical trials in breast Cancer. 23 rd ICON. Allahabad. 25th September
2010
80. Phase II/III clinical trials in Myeloma. 23 rd ICON. Allahabad, 25 th Sept 2010.
81. Adjuvant chemotherapy: role of taxanes. TMH-WCI conference, Mumbai 23 Oct
2010
82. Session Moderator on Haematological Malignancies, Indian Society of Medical
and Paediatric Oncology meeting, Bhubaneswar, 12 th Feb 2011
23

Dr Bhawna Sirohi’s CV
83. Albumin-bound Paclitaxel in breast cancer: Indian Society of Medical and
Paediatric Oncology meeting, Bhubaneswar, 12 th Feb 2011
84. Cobalt nuclear accident in Delhi: Education session Nuclear accidents, Paris, 5 th
April 2011
85. Chairman, Session on Plasma cell dyscrasias at XIII International Myeloma
workshop, Paris, 5 th May 2011
86. Neoadjuvant therapy in upper GI Cancers : breakout session at Best of ASCO,
Pune 15 th July 2011
87. Eribulin in Metastatic breast cancer : Best of ASCO, Pune 16 th July 2011
88. Triple negative breast cancer : Panelist for the abstract discussions, Best of
ASCO, Pune 16 th July 2011
89. Emerging therapies in Multiple Myeloma-Carfilzomib and Pomalidomide,
National Myeloma Summit, 6 th August 2011, Mumbai
90. Invited faculty for the meeting Multi-sectoral Partnerships for Health Promotion
and Non- Communicable Diseases (NCDs) Prevention in India, Tata Memorial
Hospital, Mumbai, 5 th Aug 2011.
91. Role of Physician in cancer care. IMA Gurgaon meeting, Gurgaon. 27 th August
2011
92. Selection of front-line chemotherapy for advanced non small cell lung cancer.
New Delhi, 30 th August 2011
93. Invited panellist for case based discussion. NET Expert forum. New Delhi. 3 rd
Sept 2011
94. Role of Physicians in diagnosis and staging of cancers. CGHS-Delhi and
Gurgaon. New Delhi. 14 th September 2011.
95. Oncology for non-oncologists- primary and emergency care. Artemis Cancer
Centre, Gurgaon. 20 th Sept 2011
96. Chemotherapy update from the latest EBCTCG overview-implications for
standard practice. TMC-WCI conference, Mumbai. 14 th Oct 2011.
97. Venous access devices –risk management. Nursing education course. Gurgaon.
20 th Oct 2011
98. Molecular profiling: Heterogeneity of adenocarcinoma and targets of therapy. F-
KOM, Gurgaon. 22 nd Oct 2011
99. Role of Physician in cancer care. Gurgaon Nursing home and diagnostic centre
association meeting, Gurgaon, 4 th Nov 2011
100. CLABSI (Central line associated blood stream infections) - A Clinicians
Perspective”. Hospital Infection Society – India (HISI meeting), Gurgaon, 17th
December 2011.
101. Lung cancer – interactive case presentation. National College of Chest
Physicians (I), Monthly Clinical Meetings, India Habitat Centre, New Delhi, 18th
December, 2011.
102. Hodgkin Lymphoma and elderly patients- moderator for the session. European
School of Oncology: Conference on Lymphoma’s and Leukaemia’s, Hotel ITC
Grand Central, Mumbai, January 6, 2012.
103. GIST – targeted therapy. Delhi NCR Oncology Meet, India Habitat Centre,
January 11, 2012.
104. Role of Physicians in Cancer Care - IMA Dwarka. January 13, 2012.
105. Modern management of colorectal cancers – RGCI GI Cancers Symposium, –
17 th February 2012, New Delhi
24

Dr Bhawna Sirohi’s CV
106. Panel discussion on Hodgkin Lymhpoma. EBM, TMC 24 th February 2012,
Mumbai
107. Debate on loco-regional issues in breast cancer- moderator. Asia Breast
Cancer Congress (ABCC). 4 th March 2012, Bangalore
108. Hormone therapy and biomarkers in breast cancer- moderator. 26 th ICON. 24 th
March 2012, Banglore
109. Advanced EBMT Training Course on European Approach to the Medical
Management of Mass Radiation Exposure. Multi-organ dysfunction syndrome. 4 th
april 2012 , Geneva
110. Best of ASCO, Jaipur, 23rd June 2012. Talks on Long term survival of
EORTC study-colorectal cancer, Advances in Chemotherapy on upper GI cancers,
chemotherapy standards in metastatic colorectal cancer
111. ICMR Task force on cancer guidelines-chairmen’s meeting, Talk on common
template for the guidelines, New Delhi, 29 th June 2012
112. Recent Advances in Surgical & Medical Gastroenterology-Elsevier workshop.
Targeted therapy in GI cancers, Bali, Indonesia, 21st July 2012
113. 27th ICON, Moderator, Case capsule discussion on colon cancer, 15th Sept
2012, Nasik
114. UAE Cancer congress (Organsiisng committee, Program coordinator),
Pathological CR in rectal cancers, Zoledronic acid in breast cancers, Neo-adjuvant
approaches in GI cancers, 12-14th Oct 2012, Dubai
115. 1st national breast cancer support group meeting, Side effects of
chemotherapy in breast cancer, 6 th Oct 2012, Pune
116. Asia pacific Virtual Meeting on Expert discussion on HCC management,
Moderator: Case capsules of HCC, 3 rd nov 2012, Mumbai
117. Colorectal Cancer Symposium 2012 , Case capsule discussion on colorectal
cancers, 8th Nov 2012 , Mumbai
118. ESMO guidelines group meeting, ESMO 2012 highlights for colorectal
cancers, 22 nd Dec 2012, Chennai
BIBLIOGRAPHY
(H- Index in March 2012 for publications =20)
Peer-reviewed Papers (71)
1. Gera M, Gera B (Sirohi B) . Unusual second malignancies in childhood
Retinoblastoma: Indian Journal of Medical and Paediatric Oncology: Vol 17 No
1, March 1996 (40-44).
2. Vaidya S, Saika S, Sirohi B, Pai S, Advani S. Avascular necrosis of bone- a
complication of aggressive therapy for acute lymphoblastic leukemia- Acta
Oncologica, 1998; 37 (2): 175-7.
3. S. Advani, S. Pai, D. Venzon, M. Adde, P. K. Kurkure, C. N. Nair, B. Sirohi, S.
D. Banavali, R. Hawaldar, B. B. Kolhatkar, T. Vats, and I. Magrath Acute
lymphoblastic leukaemia in India: An analysis of prognostic factors using a
single treatment regimen. Ann. Onc., February 1999; 10: 167 - 176.
4. Sirohi, B., Powles, R., Mehta, J., Raje, N., Kulkarni, S., Ramiah, V., Saso, R.,
Horton, C., Bhagwati, N., Singhal, S., Treleaven, J. Complete remission rate
and outcome after intensive treatment of 177 patients under 75 years of age with
IgG myeloma defining a circumscribed disease entity with a new staging
system. British Journal of Haematology 1999; 107: 656-666
25

Dr Bhawna Sirohi’s CV
5. Sirohi, B., Powles, R., Treleaven, J., Mainwaring, P., Kulkarni, S., Pandha, H.,
Bhagwati, N., Horton, C., Singhal, S., Mehta, J. The role of autologous
transplantation in patients with multiple myeloma aged 65 years and over. Bone
Marrow Transplantation 2000; 25, (5) 533-539
6. Singhal, S., Powles, R., Kulkarni, S., Treleaven, J., Sirohi, B., Millar, B.,
Shepherd, V., Saso, R., Rowland, A., Long, S., Cabral, S., Horton, C., Mehta, J.
Comparison of marrow and blood cell yields from the same donors in a doubleblind,
randomized study of allogeneic marrow versus blood stem cell
transplantation. Bone Marrow Transplantation 2000 25: (5) 501-505.
7. Kulkarni, S., Powles, R., Treleaven, J., Riley, U., Singhal, S., Horton, C.,
Sirohi, B., Bhagwati, N., Meller, S., Saso, R., Mehta, J. Chronic GVHD is
associated with long-term risk of pneumococcal infections in bone marrow
transplant patients. Blood, 2000, 95:(12) p3683-86.
8. Kulkarni, S., Powles, R., Treleaven, J., Singhal, S., Horton, C., Sirohi, B.,
Bhagwati, N., Tait, D., Saso, R., Killick, Pinkerton, R., Atra, A., Meller, S.,
Mehta, J. Melphalan/TBI is not more carcinogenic than cyclophosphamide/TBI
for transplant conditioning: follow-up of 725 patients from a single centre over
a period of 26 years. Bone Marrow Transplant 2000 25,(4) 365-370.
9. Powles, R., Sirohi, B., Kulkarni, S., Bhagwati, N., Saso, R., Raje, J., Horton,
C., Singhal, S., Mehta, J., Treleaven, J. Acute lymphoblastic leukaemia-type
intensive chemotherapy to eliminate minimal residual disease after high-dose
melphalan and autologous transplantation in multiple myeloma - A phase I/II
feasibility and tolerance study of 17 patients. Bone Marrow Transplant 2000
25: (9) 949-956.
10. Powles, R., Mehta, J., Kulkarni, S., Treleaven, J., Millar, B., Shepherd, V.,
Rowland, A., Sirohi, B., Tait, D., Horton, C., Long, S., Singhal, S. Allogeneic
blood and marrow stem cell transplantation in haematologic malignant disease:
a randomised trial. Lancet 2000, 355: 1231-1237
11. Singhal, S., Powles, R., Treleaven, J., Kulkarni, S., Sirohi, B., Horton, C.,
Millar, J., Shepherd, V., Tait, D., Saso, R., Rowland, A., Long, S., Mehta, J. A
low CD34+ cell dose results in higher mortality and poorer survival or marrow
stem cell transplantation from HLA-identical siblings: Should CD34+ cells/kg
be considered the maximum threshold? Bone Marrow Transplantation, 2000
Sep, 36(5) p489-96.
12. Sirohi B, Powles R L, Kulkani S, Rudin C, Saso R, Rigg A, Horton C, Singhal
S, Mehta J, and Treleaven J. Glomerular filtration rate prior to high dose
melphalan 200 mg/m 2 as a surrogate marker or outcome in patients with
myeloma. British Journal of Cancer 2001; 85 (3):325-332.
13. Sirohi, B., and Powles, R., : High-Dose Therapy in Patients with Multiple
Myeloma: Oncology Spectrums,2002;2 (2): Pages 86-95.
14. Sirohi B, Powles R, Kulkarni S, Rudin C, Saso R, Lal R, Singhal S, Mehta J,
Horton C, Treleaven J. Comparison of new patients with Bence-Jones, IgG and
IgA myeloma receiving sequential therapy: the need to regard these
immunologic subtypes as separate disease entities with specific prognostic
criteria. Bone Marrow Transplantation, 2001; 28:29-37.
15. Sirohi B, Kulkarni S, Powles R. Some early phase II trials in previously
untreated multiple myeloma: The Royal Marsden Experience. Seminars in
Hematology. Vol. 38. July 2001, page 209-18.
26

Dr Bhawna Sirohi’s CV
16. Sirohi B and Powles R. International Myeloma Grand Round. The Lancet
Oncology, Vol 2 (9) 2001: 571-579.
17. Sirohi B, Powles R, Mehta J, Treleaven J, Raje N, Kulkarni S, Rudin C,
Bhagwati N, Horton C, Saso R, Singhal S, Parikh P. The Implication of
compromised renal function at presentation in myeloma. Medical Oncology:
vol 18(1) 2001: 39-50
18. Singhal, S., Powles, R., Henslee-Downey, P.J., Chiang, K.Y., Treleaven, J.,
Godder, K., Kulkarni, S., van Rhee, S., Sirohi, B., Pinkerton, C.R., Meller, S.,
Mehta, J. Allogeneic transplantation from HLA-matched sibling or partially
HLA-mismatched related donors for primary refactory acute leukaemia. Bone
Marrow Transplantation, 2002; 29(4): 291-295.
19. Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Tait, D., Singhal, S., Mehta,
J. The role of post-transplantation maintenance chemotherapy in improving the
outcome of autotransplantation in adult acute lymphoblastic leukaemia. Blood,
2002, 100(5): 1641-1647.
20. Powles, R., Sirohi, B. Kulkarni, S., Treleaven, J., Rudin, C., Sankpal, S.,
Goyal, S., Horton, C., Millar, B., Saso, R., Singhal, S., Mehta, J. Collection of
peripheral blood stem cells in newly diagnosed myeloma patients without any
prior cytoreductive therapy: the first step towards an ‘operational cure’? Bone
Marrow Transplantation, 2002, 30, 479-484.
21. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S Mehta J. Response to
induction chemotherapy is not essential to obtain survival benefit from highdose
melphalan and autotransplantation in myeloma. Bone Marrow
Transplantation 2002; 30 (10): 673-9.
22. Mehta, J., Powles, R., Sirohi, B., Treleaven, J., Kulkarni, S., Saso, R., Tait, D.,
Singhal, S. Does donor-recipient ABO-incompatible protect against relapse
after allogeneic bone marrow transplantation in first remission acute myeloid
leukaemia? Bone Marrow Transplantation 2002; 29 (10): 853-9.
23. Elnenaei MO, Gruszka-Westwood AM, A’Hernt R, Matutes E, Sirohi B,
Powles R, Catovsky D. Gene abnormalities in multiple myeloma; the
relevances of TP53, MDM2, and CDKN2A. Haematologica 2003;88: 529-537.
24. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C, Atra A, Ortin
M, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S.
Thalidomide after allogeneic haematopoietic stem cell transplantation : activity
in chronic but not in acute graft-versus-host disease. Bone Marrow
Transplantation 2003;32:165-70.
25. Mehta J, Powles R, Sirohi B, Treleaven J, Swansbury GJ, Kulkarni S, Saso R,
Singhal S. Impact of cytogenetics on the outcome of autotransplantation for
acute myeloid leukaemia in first remission: is the benefit of intensive
pretransplant therapy limited to patients with good karyotypes? Bone Marrow
Transplantation 2003;32:157-64.
26. Singhal S, Henslee-Downey PJ, Polwes R, Chiang KY, godder K, Treleaven J,
Kulkarni S, Van Rhee F, Sirohi B, Pinkerton CR, Meller S, Jovanovic B, Mehta
J. Haploidentical vs autologous haematopoietic stem cell transplantation in
patients with acute leukaemia beyond first remission. Bone Marrow
Transplantation 2003;31:889-95.
27. Sirohi B, Powles R, Treleaven J, Rudin C, Kulkarni S, Frassoni F, Bacigalupo
A, Singhal S, Labopin M, Michallet M, Blaise D, Reiffers J, Meloni G, Rio B,
Horton C, Mehta J. Reassessing autotransplantation for acute myeloid
27

Dr Bhawna Sirohi’s CV
leukaemiain first remission- a matched pair analysis of autologous marrow
versus peripheral blood stem cells. Accepted for publication in Bone Marrow
Transplantation. 2003.
28. Brian GM Durie 1 , Robert A Kyle 2 ,Andrew Belch 3 , William Bensinger 4 , Joan
Blade 5 , Mario Boccadoro 6 , J Anthony Child 7 , Raymond Comenzo 8 , Ben
Djulbegovic 1 , Dorotea Fantl 9 , Gosta Gahrton 10 , Jean Luc Harousseau 11 , Vania
Hungria 12 , Douglas Joshua 13 , Heinz Ludwig 14 , Jayesh Mehta 15 , Angelina
Rodrique Morales 16 , Gareth Morgan 16 , Amara Nouel 17 , Martin Oken 18 ,
Raymond Powles 19 , David Roodman 20 Jesus San Miguel 21 , Kazuyuki
Shimizu 22 , Seema Singhal 15 , Bhawna Sirohi 19 , Peter Sonneveld 23 , Guido
Tricot 24 and Brian Van Ness 25. Myeloma management guidelines: a consensus
report from the Scientific Advisors of the International Myeloma Foundation 1 .
The Hematology Journal (2003) 4, 379-398.
29. The International Myeloma Working Group. Criteria for the classification of
monoclonal gammopathies, multiple myeloma and related disorders: a report of
the International Myeloma working Group. British Journal of Haematology
2003, 121:749-757.
30. Bronwen E Shaw, Peggs K, Bird J, Cavenagh J, Hunter A, Madrigal JA, Russell
N, Sirohi B, Towlson K, Williams C, Marks D. The outcome of unrelated donor
stem cell transplantation for patients with multiple myeloma. British journal of
Haematology 2003,123:886-895.
31. Pearson IC, Sirohi B, Powles R, Treleaven J, Mortimer PS. The prevalence and
nature of skin problems in a modern intensive Haemato-Oncology Unit,
Hematology. 2004 Oct-Dec;9(5-6):415-23.
32. B Sirohi, Powles R. Multiple Myeloma . Lancet 2004 363: 875-87.
33. Durie BG, Kyle RA, Belch A, Bensinger W, Blade J, Boccadoro M, Child JA,
Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau JL, Hungria V,
Joshua D, Ludwig H, Mehta J, Morales AR, Morgan G, Nouel A, Oken M,
Powles R, Roodman D, Miguel JS, Shimizu K, Singhal S, Sirohi B, Sonneveld
P, Tricot G, Ness BV. Myeloma management guidelines: a consensus report
from the Scientific Advisors of the International Myeloma Foundation. J
Haematol 2004, 5(3): 285-295.
34. Sirohi B, Powles R, Kulkarni S, Rudin C, Frassoni F, Bacigalupo A, Singhal S,
Vaidya S, Labopin M, Michallet M, Blaise D, Reiffers J, Meloni G, Rio B,
Treleaven J, Horton C, Mehta J. Reassessing autotransplantation for acute
myeloid leukaemia in first remission - a matched pair analysis of autologous
marrow vs peripheral blood stem cells. Bone Marrow Transplant 2004, 33 (12):
1209-14.
35. Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Singhal S. High-dose
melphalan and autotransplantation followed by post transplant maintenance
chemotherapy for acute lymphoblastic leukaemia in first remission. Bone
Marrow Transplant 2004, 33:1107-14.
36. Sirohi B., Powles R., Mehta J., Rudin C, Kulkarni S., Horton C., Saso R,
Singhal S. Treleaven J An elective single autograft with high-dose melphalan:
single-centre study of 451 patients. Bone Marrow Transplant. 2005 May 16;
[Epub ahead of print]
37. Gahrton G, Iacobelli S, Apperley J, Bandini G, Bjorkstrand B, Blade J, Boiron
JM, Cavo M, Cornelissen J, Corradini P, Kroger N, Ljungman P, Michallet M,
Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander
28

Dr Bhawna Sirohi’s CV
A, Niederwieser D.The impact of donor gender on outcome of allogeneic
hematopoietic stem cell transplantation for multiple myeloma: reduced relapse
risk in female to male transplants. Bone Marrow Transplant. 2005 Mar;35(6):609-
17.
38. Sirohi, B., Powles R, Rudin C, Singhal, S., Kulkarni, S., Saso R, Horton, C.,
Mehta, J, Treleaven J. Using the Original Infusional Induction Chemotherapy
Again as Salvage Therapy in Myeloma Patients Relapsing After One Autograft.
Hematology. 2005 Oct;10(5):361-4.
39. CL Alvares, FE Davies, C Horton, G Patel, R Powles, B Sirohi, R Zuha, A Gatt,
R Saso, JG Treleaven, CE Dearden, MN Potter, ME Ethell, GJ Morgan Long-term
outcomes of previously untreated myeloma patients: responses to induction
chemotherapy and high-dose melphalan incorporated within a risk stratification
model can help to direct the use of novel treatments, accepted Br J Haematology,
2005
40. Sirohi B, Huddart R. The management of poor-prognosis, non-seminomatous
germ-cell tumours. Clin Oncol (R Coll Radiol). 2005 Oct;17(7):543-52.
41. Prescot AP, Dzik-Jurasz AS, Leach MO, Sirohi B, Powles R, Collins
DJ.Localized COSY and DQF-COSY 1H-MRS sequences for investigating
human tibial bone marrow in vivo and initial application to patients with acute
leukemia. J Magn Reson Imaging. 2005 Oct;22(4):541-8.
42. Vaidya SJ, Ortin M, Lopez-Duarte M, Sirohi B, Powles R, Treleaven J, Richard
C. Haemopoietic progenitor cell transplantation in patients with previous history
of invasive fungal infection. Leuk Lymphoma. 2005 Aug;46(8):1143-50.
43. Sirohi B, Powles R, Chopra R, Russell N, Byrne JL, Prentice G, Potter M,
Koblinger S. Assessment of Maximum Tolerated Dose (MTD) of FK463 in
Cancer Patients Undergoing Haematopoetic Stem Cell Transplantation.- Bone
Marrow Transplant. 2006 Jul;38(1):47-51. Epub 2006 May 22.
44. Bird JM, Fuge R, Sirohi B, Apperley JF, Hunter A, Snowden J, Mahendra P,
Milligan D, Byrne J, Littlewood T, Fegan C, McQuaker G, Pagliuca A, Johnson
P, Rahemtulla A, Morris C, Marks DI; British Society of Blood and Marrow
Transplantation. The clinical outcome and toxicity of high-dose chemotherapy
and autologous stem cell transplantation in patients with myeloma or amyloid and
severe renal impairment: a British Society of Blood and Marrow Transplantation
study. Br J Haematol. 2006 Aug;134(4):385-90. Epub 2006 Jul 5
45. Sirohi B, Powles R. Epidemiology and outcomes research for MGUS, myeloma
and amyloidosis. Eur J Cancer. 2006 Jul;42(11):1671-83. Epub 2006 Jul 25.
46. Gorin NC, Fliedner TM, Gourmelon P, Ganser A, Meineke V, Sirohi B, Powles
R, Apperley J. Consensus conference on European preparedness for
haematological and other medical management of mass radiation accidents. Ann
Hematol. 2006 Oct;85(10):671-9. Epub 2006 Aug 1.
47. Sirohi B, Powles R, Morgan G, Treleaven J, Kulkarni S, Horton C, Saso R, Rolfe
D, Cook G, Shaw C, Wass J. Use of physiological doses of human growth
hormone in haematological patients receiving intensive chemotherapy promotes
haematopoietic recovery: a double-blind randomized, placebo-controlled study.
Bone Marrow Transplant. 2007 Jan;39(2):115-20. Epub 2006 Dec 4.
48. Arkenau HT, Chong G, Cunningham D, Watkins D, Agarwal R, Sirohi B,
Trumper M, Norman A, Wotherspoon A, Horwich A. The role of intrathecal
chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann
Oncol. 2007 Mar;18(3):541-5. Epub 2006 Dec 12.
29

Dr Bhawna Sirohi’s CV
49. Arkenau HT, Chong G, Cunningham D, Watkins D, Sirohi B, Chau I,
Wotherspoon A, Norman A, Horwich A, Matutes E Gemcitabine, cisplatin and
methylprednisolone for the treatment of patients with peripheral T-cell lymphoma:
the Royal Marsden Hospital experience. Haematologica. 2007 Feb;92(2):271-2.
50. Sirohi B, Powles, R, Oakervee H., Singhal S., Bishop L., Horton C., Kulkarni
S., Barnett M., Dyer P., Rintala T., Mehta J, Cavenagh J.D. Upfront Collection of
Peripheral Blood Stem Cells (PBSC) in New Patients with Myeloma Receiving
Minimal or No Prior Cytoreductive Therapy: Comparison of Two Regimes from
Royal Marsden Hospital and St. Bartholomew's Hospital. – Haematology 2007
Apr;12(2):113-5.
51. Sirohi B, Powles R, Lawrence D., Kulkarni S., Hollis H., Heming D., Sankpal
S., Patel G., Singhal S., Treleaven J. Mehta J. An Open, Randomized,
Controlled, Phase II, Single Centre, Two-Period Cross Over Study To Compare
the Quality of Life (QoL) and Toxicity Experienced on PEG Interferon (P-IFN)
with Interferon-a2b (IFN) in Patients with Multiple Myeloma (MM) Maintained
on a Steady Dose of IFN- Annals of Oncology 2007 Aug;18(8):1388-94.
52. Sirohi, B Cunningham D, Norman A, Last K, Chau I, Horwich A, Oates J,
Chong G, Wotherspoon A. Gemcitabine, cisplatin and methylprednisolone (GEM-
P) with or without Rituximab in relapsed and refractory patients with diffuse large
B cell lymphoma (DLBCL).Hematology. 2007 Apr;12(2):149-53.
53. Murphy F, Sirohi B, Cunningham D. Autotransplantation in Hodgkin
Lymphoma. Expert Rev Cancer Therapy. 2007 Mar;7(3):297-306.
54. Formica V, Wotherspoon A, Cunningham D, Norman AR, Sirohi B, Oates J,
Chong G. The prognostic role of WHO classification, urinary 5-
hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine
carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007 Apr
23;96(8):1178-82
55. Sirohi B, Ashley S, Norton A, Popat S, Hughes S, Papadopoulos P, Priest
K,O’Brien M Early response to platinum-based first line chemotherapy in non
small cell lung cancer (NSCLC) may predict survival. Journal of Thoracic
Oncology 2007 Aug;2(8):735-40.
56. Sirohi, B, Powles R, Harousseau JL, Anderson KC. The evolving background for
high-dose treatment for myeloma. Bone Marrow Transplant 2007;
Dec;40(12):1097-100.
57. Sirohi, B, Powles R. Future Challenges. Bone Marrow Transplant 2007;
Dec;40(12):1057-64.
58. Sirohi B, Cunningham D, Powles R, Murphy F, Arkenau T, Norman A, Oates J,
Wotherspoon A, Horwich A. Long-term outcome of autologous stem cell
transplantation in relapsed or refractory Hodgkin Lymphoma. Ann Oncol 2008
Jul; 19(7):1312-9. Epub 2008 Mar 19
59. Sirohi B, Powles R, Treleaven J, Kulkarni S, Saso R, Potter M, Ethell M, Morgan
G, Singhal S, Mehta J. The role of maintenance chemotherapy after
autotransplantation for acute lymphoblastic leukemia in first remission: singlecenter
experience of 100 patients. Bone Marrow Transplant. 2008 Jul;42(2):105-
12. Epub 2008 Apr 14.
60. Fliedner TM, Powles R, Sirohi B, Niederwieser D; European Group for Blood
and Marrow Transplantation (EBMT) Nuclear Accident Committee (NAC).
Radiologic and nuclear events: the METREPOL severity of effect grading system.
Blood. 2008 Jun 15;111(12):5757-8; author reply 5758-9.
30

Dr Bhawna Sirohi’s CV
61. Sirohi B, Arnedos M, Popat S, Ashley S, Nerurkar A, Walsh G, Johnston S,
Smith IE. Platinum-based chemotherapy in triple-negative breast cancer. Ann
Oncol. 2008 Nov;19(11):1847-52. Epub 2008 Jun 20 .
62. Cunningham DC, Sirohi B, Pluzanska A, Utracka-Hutka B, Zaluski J, Glynne-
Jones R, Koralewski P, Bridgewater J, Mainwaring P, Wasan H, Wang JY,
Szczylik C, Clingan P, Chan RTT, Tabah-Fisch T, and Cassidy J.Two Different
First-line 5-Fluorouracil Regimens With or Without Oxaliplatin in Advanced
Colorectal Cancer (LIFE). Ann Oncol. 2009 Feb;20(2):244-50. Epub 2008 Oct
14.
63. Sirohi B, Powles R, Singhal S, Smith K, Jones RL, Saso R, Kulkarni S, Treleaven
J, Swansbury GJ, Potter M, Morgan G, Mehta J et al. Outcome of high-dose
cytarabine-based induction therapy followed by hematopoietic stem cell
transplantation in acute myeloid leukemia. Leuk Lymphoma. 2008
Dec;49(12):2284-90.
64. Fliedner TM, Chao NJ, Bader JL, Boettger A, Case C Jr, Chute J, Confer DL, Ganser
A, Gorin N-C, Gourmelon P, Graessle DH, Krawisz R, Meineke V, Niederwieser D,
Port M, Powles R, Sirohi B, Weinstock DM, Wiley A, Coleman CN. Multi-organ
Failure in Radiation Emergency Medical Preparedness: A US/European
Consultation Workshop. Stem Cells e-published Jan 22, 2009. Stem Cells. 2009
May;27(5):1205-11
65. Sirohi, B, Powles R. Lenalidomide in Multiple Myeloma, Expert reviews
anticancer therapy. Nov 2009;9(11):1159-1570.
66. Basu B, Biswas S, Wrigley J, Sirohi B, Corrie P. Angiogenesis in cutaneous
malignant melanoma and therapeutic strategies. Expert reviews anticancer
therapy. Nov 2009;9(11):1583-1598.
67. Sirohi, B et al A randomised comparative trial of infusional ECisF (epirubicin,
cisplatin and infusional 5FU) vs conventional FEC (5FU, epirubicin and
cyclophosphamide) as adjuvant chemotherapy in early breast cancer : The
TRAFIC(TRial of Adjuvant 5FU Infusional Chemotherapy) trial. Ann Oncol.
2010 Aug;21(8):1623-9. Epub 2010 Jan 21.
68. Powles R, Sirohi B, Niederwieser D.The role of the European haematologist in a
large irradiation emergency: the European Blood and Marrow Transplantation
Society (EBMT) Nuclear Accident Committee (NAC). Health Physics 2010
98(6): 810-4.
69. Jackson C, Sirohi B, Cunningham D, Horwich A, Thomas K, Wotherspoon
A.Lymphocyte-predominant Hodgkin lymphoma--clinical features and treatment
outcomes from a 30-year experience. Ann Oncol. 2010 Oct;21(10):2061-8. Epub
2010 Mar 23.
70. Noble J, Sirohi B, Ashley S, Ladas G, Smith I.Sternal/para-sternal resection for
parasternal local recurrence in breast cancer. Breast. 2010 Oct;19(5):350-4. Epub
2010 Mar 20.
71. Cook N, Basu B, Biswas S, Kareclas P, Mann C, Palmer C, Thomas A, Nicholson
S, Morgan B, Lomas D, Sirohi B, Mander AP, Middleton M, Corrie PG. A phase
2 study of vatalanib in metastatic melanoma patients. Eur J Cancer. 2010
Oct;46(15):2671-3. Epub 2010 Aug 25.
72.
Chapters /Reviews (14)
31

Dr Bhawna Sirohi’s CV
73. Powles R, Sirohi B and Kulkarni S. Scientific evidence and expert clinical
opinion for the investigations and management of hyperleukocytosis in adults.
Chemotherapy book, Chapter 3, July 2002, pg 33-50.
74. Powles R, Sirohi B and Kulkarni S. Scientific evidence and expert clinical
opinion for the investigations and management of compressive syndromes in
adults. Chemotherapy book, Chapter 4, July 2002, pg 51-54.
75. Sirohi B, Treleaven J, Powles R, Role of Interferons, Book-Myeloma, Eds 1,
Dunitz, Edited by Mehta J Singhal S, 2001, 383-396.
76. Sirohi B, Raje N, Powles R. Autologous Haematopoietic stem cell
transplantation for multiple myeloma and AL amyloidosis, Chapter in Clinical
Bone Marrow and Blood Stem Cell Transplantation (3rd Edition). Edited by
Kerry Atkinson. Cambridge University Press. 2003, p 287
77. Sirohi B, Powles R. Leukaemia and Myeloma. Chapter 21 in cancer in Primary
Care. Eds 1, Dunitz, Edited by Martin Gore & Douglas Russell (2003)
78. Sirohi B, Cunningham D. Safety and efficacy of irinotecan plus high-dose
folinic acid and 5-FU i/v bolus for metastatic colorectal cancer patients: a pooled
analysis of two consecutive SICOG trials. Commentary Clinical colorectal
Cancer. 2005.
79. Sirohi B, Cunningham D. Salvage chemotherapy with irinotecan and cisplatin in
patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. .
Commentary Clinical colorectal Cancer. 2005.
80. Sirohi B, Powles R. Multiple Myeloma : E-learning module for European Journal
of Cancer Care , Jan 2008
81. Leary AF, Sirohi B, Johnston SR Clinical trials update: endocrine and biological
therapy combinations in the treatment of breast cancer. Breast Cancer Res. 2007
Oct 26;9(5):112
82. Sirohi, B, Smith K. Bevacizumab in the treatment of breast cancer. Expert Rev
Anticancer Ther. 2008 Oct;8(10):1559-68.
83. Sirohi B, Leary A, Johnston S. Ipsilateral Breast tumour recurrence: current
practice and recommendations. Breast J. 2009 May-Jun;15(3):268-78.
84. Basu B, Sirohi B, Corrie P.Systemic therapy for neuroendocrine tumours of
gastroenteropancreatic origin. Endocr Relat Cancer. 2010 Jan 29;17(1):R75-90
85. Sirohi B. Cancer management in the twenty-first century in India. Indian J Med
Paediatr Oncol. 2010 Apr;31(2):49-50
86. Sirohi B. New Delhi metallo-β-lactamase 1. Lancet Infect Dis. 2010
Nov;10(11):750; author reply 752-4.
87. Shrikhande SV, Sirohi B, Goel M, Barreto SG. Pancreatic neuroendocrine
tumorsIndian J Gastroenterol. 2012 Oct 3
Abstracts -260 in peer reviewed journals.
HOBBIES /INTERESTS
Photography, Cinema, Theatre, Art exhibitions, Horse-Riding, Lawn Tennis, Chess
and Reading.
32